Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).
暂无分享,去创建一个
M. Konopleva | Z. Estrov | M. Andreeff | H. Kantarjian | G. Garcia-Manero | T. Kadia | F. Ravandi | G. Borthakur | E. Jabbour | N. Daver | C. Dinardo | N. Jain | N. Short | Sa A. Wang | M. Ohanian | G. Montalban-Bravo | R. Tidwell | P. Bose | M. Yilmaz | G. Issa